We Are Seeking Stem Cell Patients Who Have Experienced Complications or Adverse Medical Events
Injured by Stem Cell Products or Suffering from Complications? You May Be Entitled to Compensation.
The future of medicine is upon us stem cell therapy. Using stem cells to regenerate or replace damaged tissue or diseased cells is a technique that is offering new life to millions of patients.
Like any other medical treatment, stem cell treatments come with a number of risks and side effects, including stem cell rejection, Graft-versus-host disease (GVHD), fatigue, bruising or other minor side effects associated with stem cell procedures.
But some stem cell products carry greater, life-threatening risks.
Most Americans feel that stem cells are safe as long as they are FDA-approved or authorized for use in clinical trials. And this absolutely should be the case.
However, stem cell companies feeling pressured to keep up with a highly competitive market may skimp on quality control and ignore safe manufacturing requirements. Corrupt stem cell companies and clinics may use unsafe manufacturing conditions to save on costs, resulting in dangerous stem cell contamination and deadly patient infections.
Stem cell manufacturers and distributors who produce dangerous, defective, or contaminated stem cell products face criminal and civil penalties. Harmed stem cell patients have the right to file a lawsuit for damages, including past and future medical expenses, lost wages, pain and suffering, and other damages.
In an effort to crack down on this dangerous practice, our stem cell litigation firm is currently seeking reports of stem cell complications and adverse reactions. Working alongside the FDA, Department of Justice (DOJ) and Department of Health and Human Services Office of the Inspector General (HHS-OIG), we are actively investigating cases of potentially dangerous stem cell products.
Stem cells are cells found naturally in the body. But they are different from the majority of our bodys cells in that stem cells come from our own embryonic development. They exist throughout our lives, acting as a preliminary supply of cells from which new cells are derived.
As our bodys cells are damaged or die, stem cells are triggered to become or help create new, healthy cells to replace them. Many types of tissues contain stem cells:
Stem cells vary depending on the tissue they are taken from. Some can become any type of cell in the body, while others can become only one type of cell. This variation is grouped into five categories:
Injecting stem cells, implanting stem cells or growing stem cells to make artificial tissues have proven effective against numerous diseases.
Doctors currently use umbilical cord cells and adult stem cells to treat diseases like leukemia, multiple myeloma, lymphoma, neuroblastoma, and sickle cell anemia. Researchers are currently testing stem cell therapies to treat other types of cancers, heart disease, spinal cord injuries, stroke, type I diabetes, Alzheimers disease, amyotrophic lateral sclerosis, Parkinsons disease, severe burns, and osteoarthritis.
Scientists are also working on developing tissue regeneration techniques to grow organs and tissue for transplant, making everything from skin grafts and new blood vessels to healthy brain cells, heart cells, and kidney cells.
Currently, the FDA has approved the following stem cell-based products for use in the United States. All come from cord blood and function to produce various blood cell types.
As part of the 21st Century Cures Act (Dec. 2016), the FDA gives several unapproved stem cell therapies Regenerative Medicine Advanced Therapy (RMAT) designation. RMAT designated products, though not FDA-approved, have some preliminary clinical evidence of effectiveness against serious or life-threatening diseases for which no alternative treatment is available.
In addition to FDA-approved and RMAT-designated stem cell products, stem cell companies across the globe are currently developing and testing stem cell therapies for use in humans. Some of the primary stem cell companies include:
Like any other medical treatment, stem cell therapy comes with a number of risks and side effects. There are indirect risks, associated with other associated procedures like radiation or chemotherapy. Then there are direct risks that come with receiving the cells themselves.
Direct risks associated with stem cell therapies are relatively minor and temporary, typically lasting until the treatment takes and the cells become established in the body. The main risk is developing GVHD, when the bodys immune system tries to reject the cells, attacking healthy cells in the process. Symptoms include rash, jaundice, fever, diarrhea, cramping and nausea.
Other side effects of stem cell therapies may include fatigue (from temporary anemia), bruising (from temporarily low platelet counts), infection (from a temporarily weakened immune system).
Doctors will evaluate a patient for any potential risks up front and plan to address these issues accordingly, delivering medications before, along with, or soon after the stem cells to alleviate any problems.
However, when stem cells are not prepared or marketed correctly, serious, and life-threatening illness can result. Poor stem cell manufacturing practices can easily lead to contaminated cells. If contaminated cells are injected, the patient may develop sepsis, leading to loss of limbs, organ failure or death.
If stem cells are marketed as one type of cell but actually contain a different type of cell, those injected stem cells may cause organ failure, develop into tumors, or simply wont work as marketed allowing the patient to progress in their illness.
Even if you receive your own stem cells (autologous stem cell therapy), you can still suffer from a laboratorys poor cell acquisition process and bad preparation techniques. Your own stem cells can still become contaminated with viruses or bacteria during improper handling, causing highly dangerous infections after injection.
As the FDA ramps up its fight against unsafe stem cell companies, more and more stem cell clinics and laboratories are being disciplined for dangerous stem cell manufacturing practices.
Some stem cell products have received FDA approval and are already on the market. Others have obtained FDA investigational new drug (IND) approval or RMAT designation. According to the National Institutes of Health (NIH), more than 1,000 clinical trials examining stem cell therapies are currently underway.
All manufacturers of FDA-regulated stem cell products must adhere to strict FDA safety guidelines regarding manufacturing practices to ensure safety, potency, and purity. When they dont, they face both criminal and civil penalties.
Injured patients have the right to file a stem cell lawsuit for financial compensation, including money to pay for past and future medical expenses, lost wages, pain and suffering, and other damages.
Since properly prepared stem cell therapies rarely cause serious complications, you may be eligible to file a stem cell lawsuit if you suffered serious injury due to a stem cell product.[See our contact information at the end of this post.]
To meet FDA current good manufacturing practices (cGMP) requirements, stem cell companies must maintain a sterile facility to prevent risk of contamination. Live stem cells must be irradiated to ensure no bacterial or viral contamination is present.
Stem cell companies must also only market their cells for uses approved by the FDA. Telling patients or doctors that a stem cell line FDA-approved for lymphoma treatment is also useful for Type I diabetes treatment is dangerous and illegal.
Many stem cell products are manufactured overseas, making efficient FDA regulation difficult. With an FDA staffing shortage, overseas stem cell companies arent worried about surprise inspections and have no reason to maintain a sterile facility or sufficient quality control testing.
Most stem cell companies know an FDA inspection is coming months in advance, giving them time to clean up equipment, falsify quality control data and hide violations.
Because of the significant threat to public health, the FDA, DOJ and HHS-OIG rely on patients, doctors, nurses, stem cell laboratory technicians and pharmaceutical sales representatives to report cases of adverse reactions to stem cell treatments, stem cell contaminations and poor manufacturing practices.
Our stem cell litigation firm is currently working with the federal government to uncover potentially dangerous stem cell products. We are interested in hearing from anyone who has experienced serious complications after stem cell therapy.
Working with our national network of dangerous drug lawyers, we can help you receive answers and compensation. Stem cell products may be the future of modern medicine. Unfortunately, there are far too many companies rushing into the field with untested or dangerous products and making wild claims of miracle cures.
Recently FDA Commissioner Scott Gottlieb M.D. said,
The potential health benefits of regenerative medicine have spurred major progress in stem-cell biology over the past several decades. But we continue to see bad actors exploit the scientific promise of this field to mislead vulnerable patients into believing theyre being given safe, effective treatments; when instead these stem cell producers are leveraging the fields hype to push unapproved, unproven, illegal, and potentially unsafe products. This is putting patients health at risk.
Until the industry and regulators can insure that all medical products are safe and used properly, we will continue to protect patients and step in when drug companies push dangerous products or make unsupported claims. If you are suffering from an adverse reaction from stem cell products, contact us right away.
We are also seeking anyone with information on FDA cGMP violations, even third-party agents, outsiders, and international parties.
Present or former stem cell laboratory technicians, quality assurance (QA) professionals, pharmaceutical representatives, stem cell company executives, other stem cell safety or quality control specialists, physicians and nurses may be eligible for significant whistleblower awards under federal and state False Claims Acts.
You need not be a U.S. citizen or even a resident to report your concerns and receive a cash award.
For more information, visit our Dangerous Drug and Defective Medical Products page. If you have information on potentially dangerous stem cell preparations or are ready to file a stem cell lawsuit, Contact Us by Email at
Read more from the original source:
Suffering Complications or Adverse Reactions to Stem Cell ...
- UC Irvine Study Reveals Risks Associated with Direct-to-Consumer Ads for Stem Cell and Exosome COVID-19 Therapies - India Education Diary - November 18th, 2023
- STEM | Description, Development, & Facts | Britannica - January 31st, 2023
- What is STEM Education? | Live Science - January 31st, 2023
- Science, Technology, Engineering, and Math, including Computer Science - ed - January 23rd, 2023
- What Does STEM Stand For? Definition, Degrees and More - January 23rd, 2023
- What Is STEM? - Definition & Resources for Teachers - January 23rd, 2023
- Science, technology, engineering, and mathematics - Wikipedia - January 23rd, 2023
- Stem Definition & Meaning - Merriam-Webster - January 23rd, 2023
- November: labblood-study | News and features - University of Bristol - November 7th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 7th, 2022
- Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and... - November 7th, 2022
- Type 2 Diabetes Stem Cell Therapy - Top U.S. Stem Cell ... - January 1st, 2022
- Cancer Drug Approvals from 2021 That Patients May Have Missed - Curetoday.com - January 1st, 2022
- Late effects in survivors of high-risk neuroblastoma following stem cell transplant with and without total body irradiation - DocWire News - January 1st, 2022
- The new life of a teenager with a strange tumor on his face after the operation - Market Research Telecast - January 1st, 2022
- Best of what was new in diabetes health for 2021 - Dickson Post - January 1st, 2022
- Hematopoietic Stem Cell Transplantation - StatPearls ... - December 22nd, 2021
- Autologous Stem Cell Transplant for Multiple Myeloma - December 22nd, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 22nd, 2021
- Adaptation Is Key to Advancing Care for Adult Patients With Leukemia - OncLive - December 22nd, 2021
- FDA Approves First Drug to Prevent Graft Versus Host Disease | FDA - FDA.gov - December 22nd, 2021
- Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients - Yahoo Finance - December 22nd, 2021
- After throwing goodbye party, woman with cancer finds hope close to home in Austin - Austin American-Statesman - December 22nd, 2021
- Dr. K.M. Cherian Heart Foundation & Educational Society Organized Cme Programme & Workshop On Cell Culture And Regenerative Medicine - APN... - December 22nd, 2021
- Namesake of new center a young man in love with the pursuit of knowledge - The Saint Anselm Crier - November 7th, 2021
- Red Cross blood drive focuses on sickle cell disease fight - Palladium-Item - November 7th, 2021
- Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - KULR-TV - November 7th, 2021
- 1st CRISPR Gene Editing Trial Slated to Open in Severe SCD Patients - Sickle Cell Anemia News - April 4th, 2021
- Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network - April 4th, 2021
- Timely Bone Marrow Transplant by Fortis gives new lease of life to a patient with Multiple Myeloma - APN News - April 4th, 2021
- Kirron Kher is suffering with Multiple Myeloma: Know the causes, symptoms and more about this type of blood cancer - Jagran English - April 4th, 2021
- Decitabine Improved Outcomes for Patients With Refractory Prolonged Isolated Thrombocytopenia - Hematology Advisor - April 4th, 2021
- Lake in the Hills police officer and father of 4 kids battling rare cancer forced to retire - Lake and McHenry County Scanner - April 4th, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 4th, 2021
- Boxcar Scars Market |Exclusive Report on Latest Trends and Market Growth Opportunities - BioSpace - April 4th, 2021
- Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult... - April 4th, 2021
- BeyondSpring Announces Submission of New Drug Application to US FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of... - April 4th, 2021
- Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today - February 14th, 2021
- Roche receives first FDA clearance for urine sample type for BK virus quantitative test to aid in the improvement of care for transplant patients -... - February 14th, 2021
- Energy drinks may damage the heart, researchers warnshould the FDA get involved? - Cardiovascular Business - February 14th, 2021
- FDA Approves G1 Therapeutics' COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced... - February 14th, 2021
- Easter Ross mum of blood cancer tot urges would-be stem cell donors to show the love this Valentine's Day; Alness lass Adeline Davidson's plight... - February 14th, 2021
- Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas... - February 14th, 2021
- Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Understanding bone marrow transplant: The guidelines and the protocols - The New Indian Express - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Mobilize family caregivers to speed the rollout of Covid-19 vaccines - STAT - February 4th, 2021
- People With Cancer Should Receive COVID-19 Vaccine, Experts Say - Cancer Health Treatment News - February 4th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f - PharmiWeb.com - February 4th, 2021
- APOE Tied to Increased Susceptibility to SARS-CoV-2 | ALZFORUM - Alzforum - February 4th, 2021
- Transforming Outcomes in Advanced CSCC with Immunotherapy - LWW Journals - February 4th, 2021
- Ashley Cain is living his worst nightmare as his baby daughter battles leukaemia in hospital - The Sun - February 4th, 2021
- Canada's blood supply has a diversity problem and people are dying because of it - CBC.ca - February 1st, 2021
- Autologous Stem Cell and Non Stem Based therapies Market Share, Size 2021 Global Industry Future Trends, Growth, Strategies,, Segmentation, In-depth... - February 1st, 2021
- Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical... - February 1st, 2021
- Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA... - February 1st, 2021
- Disabled People Are Waiting, Anxiously, For Lifesaving Covid-19 Vaccinations - Forbes - February 1st, 2021
- Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme - Belfast Telegraph - February 1st, 2021
- Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation - Science Advances - February 1st, 2021
- The Need for New Biological Targets for Therapeutic Intervention in COPD - Pulmonology Advisor - February 1st, 2021
- What Patients With Cancer, Survivors Need to Know About the Emergency Use Authorization of COVID-19 Vaccine - Curetoday.com - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- Are Hiccups a Sign of the New Coronavirus? - Healthline - December 19th, 2020
- KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective... - December 19th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 19th, 2020
- Even if You've Had COVID-19 You Still Need the Vaccine - Healthline - December 19th, 2020
- The Link Between Cancer and Metabolic Dysfunction - Technology Networks - December 19th, 2020
- Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -... - December 19th, 2020
- Gene therapy gives man with sickle cell disease the chance for a better future - Science Codex - December 3rd, 2020
- Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous... - December 3rd, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 3rd, 2020
- Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed - December 3rd, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary - December 3rd, 2020
- Coinfection: more than the sum of its parts - Science Codex - November 19th, 2020
- Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to... - November 17th, 2020
- FDA Approves Merck's KEYTRUDA in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple?Negative Breast... - November 17th, 2020
- Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News - November 17th, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 17th, 2020
- UH announces participation in clinical trial testing antibodies to treat COVID-19 in adults - News 5 Cleveland - November 7th, 2020